ArticleProceedings of the National Academy of Sciences of the United States of America2019
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 2 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Corticosteroid-resistant immune-related adverse events: a systematic review.Journal for immunotherapy of cancer · 2024Pooled it
- Adaptation of the Porcine Pituitary Transcriptome, Spliceosome and Editome during Early Pregnancy.International journal of molecular sciences · 2023Pooled it
- Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.Oncoimmunology · 2024Trial
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer.Biomolecules · 2026Review
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice.Medical sciences (Basel, Switzerland) · 2026Review
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Immune-Mediated Hypophysitis: An Updated Review.Journal of clinical medicine · 2026Review
- Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026Review
- When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management.Pulmonary therapy · 2026Review
- Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches.Journal of liver cancer · 2026Review
- Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and Taxane Chemotherapy.Clinical case reports · 2026Article
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.Journal for immunotherapy of cancer · 2026Article
- Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer.Frontiers in immunology · 2026Article
- FLASH radiotherapy and immunotherapy synergy: mechanisms, strategies, and clinical translation prospects.Frontiers in immunology · 2026Review
- From inflammatory phenotypes to clinical decisions: a stratified diagnostic and therapeutic framework for CIP.Frontiers in immunology · 2026Review
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Immune checkpoint (IC) therapy provides substantial benefits to cancer patients but can also cause distinctive toxicities termed immune-related adverse events (irAEs). Biomarkers to predict toxicities will be necessary to improve management of patients receiving IC therapy. We relied on serological analysis of recombinant cDNA expression libraries to evaluate plasma samples from patients treated with IC therapy and identified autoantibodies, both in pretreatment and on-treatment samples prior to the development of irAEs, which correlate with the development of immune-related hypophysitis (anti-GNAL and anti-ITM2B autoantibodies) and pneumonitis (anti-CD74 autoantibody). We developed an enzyme-linked immunosorbent assay and tested additional patient samples to confirm our initial findings. Collectively, our data suggest that autoantibodies may correlate with irAEs related to IC therapy, and specific autoantibodies may be detected early for the management of irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.